#None #Everest Group #Zifo Technologies #AI in Science

Zifo Emphasizes New Everest Group Findings on Science-First IT Requirements

In the realm of life sciences, particularly within the biopharma sector, the integration of technology into scientific practices is critical. Recently, Zifo Technologies, a leader in data-driven informatics for science-oriented organizations, spotlighted the latest research from Everest Group titled 'Embedding Scientific Expertise at the Core of Life Sciences IT Service Delivery.' This comprehensive report reveals vital insights into the necessity of embedding scientific knowledge in IT processes to drive successful digital transformation.

As the world witnesses an acceleration in scientific discoveries, a disconnect has emerged between these breakthroughs and the informatics systems that support them. Traditional data management approaches and legacy systems have not kept pace with the rapid advancements in scientific research, resulting in a significant gap in efficiency and accuracy.

The Challenge in Current Systems

Zifo emphasizes that the ongoing AI boom further highlights this issue. While generic technology platforms boast speed and efficiency, they often falter when confronting the complex workflows scientists depend on. Zifo posits that without a foundational understanding of biological, chemical, and physical sciences, organizations risk deploying ineffective IT solutions. This sentiment is echoed in Everest Group's research, which illustrates that even the most sophisticated AI models can fail if they lack alignment with real scientific principles.

The report outlines several critical areas where the establishment of scientific contexts within IT can mitigate enterprise risks. For instance, reliance on generic corporate IT frameworks can lead to:

• - Compliance Exposure: The opaque nature of AI models can result in compliance violations and lasting damage to a firm's reputation with regulators.
• - Outcome Risks: Inconsistencies in decisions during clinical trials can yield unpredictable manufacturing quality.
• - Loss of Trust: Diminished confidence from scientists, clinicians, and regulatory bodies in digital platforms.
• - Reputational Damage: The ramifications of disseminating flawed scientific data.
• - Wasted Investments: High rates of unsuccessful AI pilots and underutilization of sophisticated systems.
• - Scaling Failures: Insufficient scientific depth in AI projects can cause stagnation in proof-of-concept initiatives, leading to poor return on investment.

Benefits of a Science-First IT Approach

The report highlights that while not every back-office operation necessitates deep scientific insight, such knowledge becomes indispensable in highly regulated and complex areas. Notably, companies that prioritized scientific expertise in areas like drug discovery reported increased value, with 77% noting its importance there, 73% in clinical development, and 37% in manufacturing operations. A striking 80% of pharmaceutical executives now view scientific acumen as pivotal in future differentiation, with 40% pinpointing it as a current major decision factor.

A Blueprint for Transition

To effectively transition towards a science-first IT infrastructure, Everest Group proposes a pragmatic four-step strategy:
1. Assess: Evaluate current operations to determine how deeply science is integrated and identify a baseline for improvement.
2. Embed: Establish the necessary data and governance frameworks to facilitate science-driven IT processes.
3. Scale: Build integrated delivery teams that harmonize robust technical skills with requisite scientific expertise.
4. Institutionalize: Standardize this science-first framework across the entire organization to ensure consistent application in all areas.

In conclusion, the pressures of fast-evolving science demand a reevaluation of how organizations utilize technology in supporting their research initiatives. As Zifo makes clear, integrating scientific understanding into IT services is not merely advantageous; it is a necessary evolution in delivering meaningful results in the biopharma sector. This shift not only protects enterprises from risks associated with generic IT frameworks but also enhances the reliability and efficiency of their scientific outputs. For more insight from the Everest Group report, visit Zifo's official page at Zifo Scientific IT Service.